(NASDAQ: ACAD) Acadia Pharmaceuticals's forecast annual revenue growth rate of 13.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Acadia Pharmaceuticals's revenue in 2024 is $813,806,000.On average, 7 Wall Street analysts forecast ACAD's revenue for 2024 to be $157,843,110,646, with the lowest ACAD revenue forecast at $155,704,161,082, and the highest ACAD revenue forecast at $162,104,487,686. On average, 7 Wall Street analysts forecast ACAD's revenue for 2025 to be $174,178,829,889, with the lowest ACAD revenue forecast at $168,809,481,600, and the highest ACAD revenue forecast at $180,189,896,090.
In 2026, ACAD is forecast to generate $199,595,419,358 in revenue, with the lowest revenue forecast at $188,811,121,818 and the highest revenue forecast at $217,067,197,399.